Year: 2020

If you are looking for another successful biotech story in 2020, then look away now. Shares of Amarin (AMRN) have been under the cosh this year, as the company has battled its way through the courts to no avail.Amarin lost a patent case, and then its appeal too, against generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s, who have their own plans for versions of Amarin’s high triglyceride treatment Vascepa. Investors have jumped ship in the meantime, sending shares down by a mighty 80% year-to-date.But conversely, if you are looking to pick up some shares on the cheap, SBV Leerink …read more […]

Zoom Video Communications (Nasdaq: ZM) has been nothing short of a stock market sensation in 2020.
It entered the year at $68. Now it trades for more than $480.
That is what we call a “seven-bagger” in this business.

If you owned $10,000 worth of Zoom shares on January 1, those shares are now worth more than $70,000.
I most definitely wish I had owned shares of Zoom on January 1 and held through today…
But if I did, I can tell you the first thing I would do…
I would sell them. Immediately.
Zoom’s Spectacular Run
I don’t dislike Zoom’s business. Quite the contrary, actually.
Zoom produces what …read more […]

A Canadian prosecutor says by requesting the inclusion of additional evidence the defense team for a Chinese executive wanted in the United States is coming close to turning an extradition hearing into a trial. Canada arrested the chief financial officer of Huawei at Vancouver’s airport in late 2018. The U.S. wants Meng Manzhou, the daughter of Huawei’s founder, extradited to face fraud charges. …read more […]

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] …read more […]

Micron reported Q4 results Tuesday that topped Street’s expectations, posting $6.06B in revenue versus the estimated $5.9B and $1.08 in earnings per share versus the expected $0.99 per share. The semiconductor design company nearly doubled its profit, adding more than $1 billion in sales from 2019, thanks in part to strong cloud and consumer sales since the start of the COVID-19 pandemic. Yahoo Finance’s Jared Blikre breaks down the details. …read more […]

We’ve been dealing with a bifurcated market for most of 2020.
Value stocks have been the babies tossed out with the bathwater. Meanwhile, growth stocks have flourished.
The Vanguard Growth ETF (NYSE: VUG) has left the Vanguard Value ETF (NYSE: VTV) by the side of the road.
We are seeing bifurcation not only at the broadest level but also at the sector-specific level. And the divergence for one industry is about to get a lot wider. The great thing about this is that it offers both value and growth.
Back in the Black… Market
Last week, the Canadian cannabis sector was pushed lower.
It’s already been …read more […]

Yahoo Finance’s Seana Smith and Myles Udland report breaking news from Disney saying that the company will layoff 28,000 employees from across its Parks, Experiences, and Consumer Products segments. …read more […]

…read more […]

USA TODAY reached out to tax attorneys and legal experts to get their reaction to the New York Times report on Trump’s taxes. Here’s what they said. …read more […]

Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine’s safety in older adults, a group at increased risk of severe complications from COVID-19. The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study’s lead researchers from Emory University in …read more […]

Put one “Battery Day” in the books, folks. On Tuesday, Sept. 22, CEO Elon Musk finally held his long-awaited presentation running down everything Tesla (TSLA) plans to do over the next decade to cut the cost of batteries, and extend the range (and lower the price) of Tesla’s electric cars.One of the key revelations: In an effort to accelerate the conversion of 300 million American cars from gasoline engines to electric, Tesla is pioneering a method of using “table salt (sodium chloride) to basically extract the lithium” … from 10,000 acres of Nevadan clay, ensuring plentiful supply of the metal …read more […]

The first rule that applies to healthcare developers is: “do not mess with the FDA.” Case in point: Shares of vaccine maker Inovio (INO) crashed by 33% over the past two trading sessions, as a result of the FDA halting the planned Phase 2/3 clinical trial of its DNA COVID-19 vaccine candidate INO-4800.The study has been put on hold, with the FDA citing the need for more questions regarding the trial. Inovio stated it will address the questions in October, following which, the FDA has 30 days to decide whether the trial can go ahead.Inovio’s shares have been subject to …read more […]

…read more […]

According to a report from Bloomberg, a group of 60 scientists have recommended that Pfizer withhold its vaccine until November for safety and efficacy. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus. …read more […]

Lonza is confident that U.S. and Swiss plants it is building to help make Moderna’s COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday. New production lines at Lonza’s site in Portsmouth, New Hampshire, aim to start making vaccine ingredients in November, while three lines in Visp, deep in a valley in the Swiss Alps – to supply 300 million vaccine doses annually – should begin delivering by December. …read more […]